Literature DB >> 19713988

Does PPI therapy predispose to Clostridium difficile infection?

Chaitanya Pant1, Phillip Madonia, Anil Minocha.   

Abstract

Clostridium difficile infection (CDI) has emerged as a problem of epidemic proportions. Previous exposure to broad-spectrum antibiotics remains the most important predisposing factor for the disease. However, PPIs are increasingly being overprescribed and recent research has, therefore, focused on the association between PPI therapy and CDI. While the data remain observational, increasing evidence exists for at least a modest association between PPI use and CDI.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19713988     DOI： 10.1038/nrgastro.2009.128

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  28 in total

1.  Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001.

Authors:  Lennox K Archibald; Shailen N Banerjee; William R Jarvis
Journal:  J Infect Dis       Date:  2004-04-20       Impact factor: 5.226

2.  Clostridium difficile infection in hospitals: risk factors and responses.

Authors:  Thomas J Louie; Jon Meddings
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

3.  Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec.

Authors:  Karl Weiss
Journal:  Clin Infect Dis       Date:  2006-03-01       Impact factor: 9.079

4.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

5.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

Review 6.  Diagnosis and treatment of Clostridium difficile colitis.

Authors:  R Fekety; A B Shah
Journal:  JAMA       Date:  1993-01-06       Impact factor: 56.272

7.  Gastric acid suppression does not promote clostridial diarrhoea in the elderly.

Authors:  S Shah; A Lewis; D Leopold; F Dunstan; K Woodhouse
Journal:  QJM       Date:  2000-03

8.  Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis.

Authors:  Richard M Cadle; Mohammad D Mansouri; Nancy Logan; Denise R Kudva; Daniel M Musher
Journal:  Am J Health Syst Pharm       Date:  2007-11-15       Impact factor: 2.637

9.  Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors.

Authors:  K J Walker; S S Gilliland; K Vance-Bryan; J A Moody; A J Larsson; J C Rotschafer; D R Guay
Journal:  J Am Geriatr Soc       Date:  1993-09       Impact factor: 5.562

10.  Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?

Authors:  Robin L P Jump; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191
View more
  9 in total

1.  PPI therapy: PPI plus aspirin for secondary cardiovascular disease prevention.

Authors:  Siew C Ng; Francis K L Chan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-09-13       Impact factor: 46.802

Review 2.  Stress-related mucosal disease in the critically ill patient.

Authors:  Marc Bardou; Jean-Pierre Quenot; Alan Barkun
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-01-06       Impact factor: 46.802

Review 3.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 4.  Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis.

Authors:  Lukas Buendgens; Alexander Koch; Frank Tacke
Journal:  World J Crit Care Med       Date:  2016-02-04

5.  Cost-utility of aspirin and proton pump inhibitors for primary prevention.

Authors:  Stephanie R Earnshaw; James Scheiman; A Mark Fendrick; Cheryl McDade; Michael Pignone
Journal:  Arch Intern Med       Date:  2011-02-14

6.  Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions.

Authors:  V K Viswanathan; M J Mallozzi; Gayatri Vedantam
Journal:  Gut Microbes       Date:  2010-06-16

7.  Predictors of Clostridium difficile infection severity in patients hospitalised in medical intensive care.

Authors:  Nagham Khanafer; Abdoulaye Touré; Cécile Chambrier; Martin Cour; Marie-Elisabeth Reverdy; Laurent Argaud; Philippe Vanhems
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

8.  A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol.

Authors:  Stephen J Allen; Kathie Wareham; Caroline Bradley; Wyn Harris; Anjan Dhar; Helga Brown; Alwyn Foden; Way Yee Cheung; Michael B Gravenor; Sue Plummer; Ceri J Phillips; Dietrich Mack
Journal:  BMC Infect Dis       Date:  2012-05-06       Impact factor: 3.090

Review 9.  Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.

Authors:  Anca Trifan; Carol Stanciu; Irina Girleanu; Oana Cristina Stoica; Ana Maria Singeap; Roxana Maxim; Stefan Andrei Chiriac; Alin Ciobica; Lucian Boiculese
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.